Table 4.

Factors associated with increased risk of VTE in patients with NSCLC

Patients Group	SHR	95% CI	P-value
Tumor histology (%)
Non-adenocarcinoma	1
Adenocarcinoma	2.40	1.11–5.19	0.027
ECOG PS
0–1	1
2–3	1.91	1.18–3.09	0.008
EGFR gene
Mutated	1
Wild	1.81	1.07–3.07	0.028
Age
≥ 60	1
< 60	1.27	0.79–2.02	0.324
Sex
Female	1
Male	1.03	0.63–1.66	0.920
Tumor Stage
Distant metastasis	1
Localized	1.18	0.67–2.07	0.569
KRAS gene
Wild	1
Mutated	1.10	0.52–2.32	0.814

Abbreviations: CI confidence interval, ECOG Eastern Cooperative Oncology Group, SHR Sub-distribution hazard ratio, NSCLC non-small cell lung cancer, PS performance status, VTE venous thromboembolism

*The variables were entered into the Fine-Gray regression model and included age, gender, ECOG PS (0–1 vs. 2–3), EGFR (mutated vs. wild), KRAS (mutated vs. wild), tumor histology (adenocarcinoma vs. nonadenocarcinoma), and tumor stage (localized stage vs. distant metastasis). All variables were shown in the table